Genetically engineered probiotics company ZBiotics raises $12m in Series A funding

Access more as a FoodBev subscriber

Sign up to FoodBev and unlock more insights from the international food and beverage industry. Subscribers have access to webinars, newsletters, publications and more...

Subscribe now >

Domino September - Website Banner - GS1 - 300x250.gif

Genetically engineered probiotics company ZBiotics raises $12m in Series A funding

Melissa Bradshaw

4 September 2024

Funding & Investments

Genetically engineered probiotics company ZBiotics raises $12m in Series A funding

ZBiotics, a US-based food-tech company bringing ‘world-first’ genetically engineered probiotics to market, has raised $12m in a Series A funding round.

The round was led by Spring Tide Capital and saw participation from Access Capital, Seamless Capital, Goat Rodeo Capital and Seaside Ventures. ZBiotics will use the funding to meet growing demand, spearhead retail expansion and drive continued R&D in a new sector.

The company’s mission is to deliver a new range of genetically engineered probiotic products that can address the unique and newly arising biological challenges of modern living. Its flagship product, Pre-Alcohol Probiotic Drink, mimics the function of the liver by breaking down the toxic byproduct of alcohol, acetaldehyde, aiming to help consumers feel better the day after drinking.

With the funds from its Series A round, ZBiotics plans to bring additional use-case probiotics to market. Leveraging the same technology used to develop its Pre-Alcohol Probiotic Drink, it will provide additional solutions for consumers looking to prioritise different aspects of their health.

The company’s second product is due to launch in the coming weeks, which will focus on microbial diversity in the gut and its associated benefits. The company’s R&D team is actively exploring products that will address a range of concerns including sleep, vaginal health and athletic performance.

Zack Abbott, co-founder and CEO of ZBiotics, said: “Genetic engineering allows us to make totally new products that address real-world consumer needs, and we're witnessing a growing interest in our technology and brand”.

He added: “In a market that craves real solutions, we've shown that being a proudly GMO company prioritising transparency resonates with consumers, driving ZBiotics' momentum”.

Investor Spring Tide Capital’s co-managing partner, Adam Ramada, commented: “Off of the breakout success of their first product, ZBiotics has more than doubled sales every year, selling over five million units cumulatively and reaching company-wide profitability in 2023”.

“We are thrilled to support the team as they continue to expand their revolutionary probiotic platform across many more exciting use cases that address everyday consumer pain points.”